Muscarine

STNR Creations Launches Revolutionary Amanita Mushroom Gummies

Retrieved on: 
Thursday, January 18, 2024
Gram, Relaxation, Serotonin, Cannabinoid, Delta, Movement, Muscimol, System, Ibotenic acid, Muscarine, Medicine, Mushroom

ORLANDO, Fla., Jan. 18, 2024 /PRNewswire/ -- STNR Creations, a trailblazer in hemp-derived and natural wellness products, proudly introduces its latest breakthrough: Energizing Amanita Mushroom Gummies, aptly named 'Not Your Grandma's Portobellos.' Expertly crafted, these gummies present a novel fusion of Amanita Muscaria with a special blend of cannabinoids, offering a safe, legal, and invigorating microdosing experience. This pioneering combination is designed to provide an unparalleled natural energy boost, opening new vistas in holistic health and well-being.

Key Points: 
  • ORLANDO, Fla., Jan. 18, 2024 /PRNewswire/ -- STNR Creations, a trailblazer in hemp-derived and natural wellness products, proudly introduces its latest breakthrough: Energizing Amanita Mushroom Gummies, aptly named 'Not Your Grandma's Portobellos.'
  • Renowned for infusing innovation into the hemp industry with their 3 Gram Disposable vape device, STNR Creations now expands its horizons with the introduction of 'Not Your Grandma's Portobellos' Amanita Mushroom Gummies.
  • Shaun Province, Vice President of Sales at STNR Creations, states, "Our 'Not Your Grandma's Portobellos' Amanita Mushroom Gummies represent our dedication to fusing ancient wisdom with modern innovation.
  • The 'Not Your Grandma's Amanita Mushroom Gummies' are more than just a product launch; they signify a movement towards redefining natural supplements.

Eighty Six Enters the Legal Psychedelics Market With Launch of Fun Guy Amanita Mushroom Gummies

Retrieved on: 
Wednesday, February 22, 2023
Psilocybin, Muscarine, Serotonin, HHC, Central nervous system, Synesthesia, Ground substance, Ibotenic acid, Muscimol, Hallucination, THC, GABA, Amanita muscaria, The Eighty-Six Years of Eubie Blake, Multimedia, Nightclub, Mushroom, Amanita

Curious consumers all over the country now have access to a lighter, brighter psychedelic trip with Fun Guy.

Key Points: 
  • Curious consumers all over the country now have access to a lighter, brighter psychedelic trip with Fun Guy.
  • Fun Guy enters the market with three classic flavors – BlueRazz, Strawberry, and Watermelon.
  • Each gummy contains 350mg of Amanita Muscaria, a federally legal medley of mushrooms that deliver a chilled-out psychoactive experience.
  • Amanita mushrooms, otherwise known as  the Amanita Muscaria, is an easily recognizable red mushroom dotted with white specs on its cap.

Galaxy Treats Launches Line of Psychadelic Amanita Mushroom Gummies

Retrieved on: 
Thursday, January 12, 2023
Substance-related disorder, Overalls, Ibotenic acid, Amanita, GABA, Muscimol, Gummy candy, Psilocybin, Relaxation, Telephone, Delta, Growth, Serotonin, Amanita muscaria, Sale, Hallucination, Muscarine, Legal status of psychoactive Amanita mushrooms, Mushroom

Amanita mushrooms (Amanita Muscaria) are easily recognizable, featuring soft, white bodies and stunning red caps with white spots.

Key Points: 
  • Amanita mushrooms (Amanita Muscaria) are easily recognizable, featuring soft, white bodies and stunning red caps with white spots.
  • Packed with 350mg of amanita mushroom extract in each gummy, Galaxy Treats Amanita Mushroom Gummies offer a mildly psychedelic experience that has been referred to as "chill" and "relaxing."
  • Currently, amanita mushroom gummies and other products containing amanita extracts are mostly legal.
  • Galaxy Treats is an industry-leading rare cannabinoid brand offering a premium selection of hemp-derived products including Delta-8 Gummies, Delta 9 Gummies, HHC Gummies, THC-O Gummies, THC-O/HHC Disposables, and now, legal psychedelic mushroom gummies.

Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook

Retrieved on: 
Thursday, May 13, 2021
Communication, Forward-looking statement, Muscarinic agonists, XC2, Drug discovery, Muscarine, Preclinical development, Health sciences, Pharmacology, Articles

ANAVEX\xc2\xae2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.

Key Points: 
  • ANAVEX\xc2\xae2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • Fox Foundation for Parkinson\xe2\x80\x99s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX\xc2\xae2-73 for the treatment of Parkinson\xe2\x80\x99s disease.
  • These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference

Retrieved on: 
Monday, April 26, 2021
Communication, Forward-looking statement, XC2, Muscarinic agonists, Muscarine, Articles

ANAVEX\xc2\xae2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.

Key Points: 
  • ANAVEX\xc2\xae2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • Fox Foundation for Parkinson\xe2\x80\x99s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX\xc2\xae2-73 for the treatment of Parkinson\xe2\x80\x99s disease.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.\n"

Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021

Retrieved on: 
Thursday, February 18, 2021
Branches of biology, Muscarinic agonists, Quaternary ammonium compounds, Homeostasis, Physiology, Muscarine, Biology

Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, is scheduled to present on Thursday, February 25th, 2021 at 12:00 p.m. EST and will discuss the Company's progress and outlook.

Key Points: 
  • Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, is scheduled to present on Thursday, February 25th, 2021 at 12:00 p.m. EST and will discuss the Company's progress and outlook.
  • ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimers disease.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021

Retrieved on: 
Monday, February 8, 2021
Branches of biology, Neuroscience, Muscarinic agonists, Communication, Forward-looking statement, Quaternary ammonium compounds, Physiology, Neurochemistry, Muscarine, Muscarinic acetylcholine receptor

Management will host a conference call on Thursday, February 11, 2021 at 4:30 pm Eastern Time to review financial results and provide an update on its clinical programs and corporate highlights.

Key Points: 
  • Management will host a conference call on Thursday, February 11, 2021 at 4:30 pm Eastern Time to review financial results and provide an update on its clinical programs and corporate highlights.
  • ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Retrieved on: 
Wednesday, November 25, 2020
Branches of biology, Neuroscience, Muscarinic agonists, Acetylcholine receptors, Neurochemistry, Quaternary ammonium compounds, Muscarinic acetylcholine receptor, Neurophysiology, Muscarine

The webcast will be archived for a period of 30 days following the conclusion of the live event.

Key Points: 
  • The webcast will be archived for a period of 30 days following the conclusion of the live event.
  • Anavexs lead drug candidate, ANAVEX2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimers disease.
  • ANAVEX2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma

Retrieved on: 
Friday, May 1, 2020
Asthma, Respiratory therapy, Quaternary ammonium compounds, Long-acting beta-adrenoceptor agonist, Muscarine, Medical specialties, Medicine, Health

If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.

Key Points: 
  • If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.
  • Under the agreement, Sosei Heptares is entitled to certain development and sales-based milestones, and royalties on net sales upon successful commercialisation of Enerzair Breezhaler.
  • Shinichi Tamura, President and CEO of Sosei Heptares, commented:"The recommendation for the approval of Enerzair Breezhaler is a great step towards it becoming available to the many uncontrolled asthma patients in the European Union.
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.

Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma

Retrieved on: 
Friday, May 1, 2020
Asthma, Respiratory therapy, Quaternary ammonium compounds, Long-acting beta-adrenoceptor agonist, Muscarine, Medical specialties, Medicine, Health

If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.

Key Points: 
  • If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.
  • Under the agreement, Sosei Heptares is entitled to certain development and sales-based milestones, and royalties on net sales upon successful commercialisation of Enerzair Breezhaler.
  • Shinichi Tamura, President and CEO of Sosei Heptares, commented:"The recommendation for the approval of Enerzair Breezhaler is a great step towards it becoming available to the many uncontrolled asthma patients in the European Union.
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.